A phase II trial suggests that anti-CD38 antibody daratumumab is effective as a standalone therapy for heavily treated multiple myeloma.…
Interim analysis of a phase III study finds that adding the new anti-CD20 monoclonal antibody obinutuzumab to standard bendamustine chemotherapy…
Findings from the PERSIST-1 study of patients with myelofibrosis suggest that pacritinib is significantly more effective than best available therapy…
An interim analysis of a large phase III study suggests that the combination of ibrutinib and bendamustine/rituximab (BR) improves outcomes…
DAVID ROSS CAMIDGE, MD, PHD, of the University of Colorado Denver answers the question what is the future for PD…
DAVID ROSS CAMIDGE, MD, PHD, of the University of Colorado Denver discusses the novel investigational agents for crizotinib resistant ALK-positive…
DAVID ROSS CAMIDGE, MD, PHD, of University of Colorado Denver discusses the role of T790M mutations in resistance to first…
This was my discussion at the ASCO Annual Meeting June 1, 2015 with Dr. Petros Grivas, medical oncologist specializing in…
Findings from a phase I/II study suggest that nivolumab is safe and effective in advanced liver cancer. Based on the…
Findings from a randomised phase III study indicate that PD-1 immunotherapy is an effective treatment option for patients with non-squamous,…
Dr. Mark Kris, MD of Memorial Sloan Kettering discusses the role of MET in NSCLC and why earlier TKIs and…
Dr. Mark Kris of Memorial Sloan Kettering discusses phase II study of cabozantinib in RET rearranged NSCLC at the annual…
This was my interview with Dr. Alok Khorana of the Cleveland Clinic at the ASCO Annual Meeting on May 30,…
This is my conversation with Dr. Alok Khorana, Director of the GI Malignancy Program at the Cleveland Clinic. Dr. Khorana…
Dr. Mark Kris, MD or Memorial Sloan Kettering discuss the role of BRAF mutations in NSCLC and the potential treatment…
Dr. Mark Kris, MD of Memorial Sloan Kettering discusses the Lung Cancer Mutation Consortium and the role of Next Generation…
At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Eleni Efstathiou (The University of Texas MD Anderson Cancer…
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany) summarises…
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Michael Untch (HELIOS Klinikum Berlin-Buch, Berlin, Germany)…
At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Catherine Kelly (Mater Misericordiae University Hospital, Dublin, Ireland) reviews…
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany) describes…
Michael Kolodziej, MD, National Medical Director, Oncology Strategies, Aetna, Inc. talks about Next Steps in Oncology Payment Reform for Established…
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Michael Untch (HELIOS Klinikum Berlin-Buch, Berlin, Germany)…
Roberta L. Buell, Principal, OnPoint Oncology, LLC discusses the Top 2015 Reimbursement Issues & ICD-10 Update from the Coding Mistress
Robert Baird Jr., RN, MSA, Chief Executive Officer, Dayton Physicians Network discusses Payment Reform for Established Provider & Payer Teams
David Eagle discusses what Are the Key Cost Drivers of Cancer Care moving forward at the COA meeting in Orlando
At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Catherine Kelly (Mater Misericordiae University Hospital, Dublin, Ireland) reviews…
James W. Hodge, PhD, MBA, Investigator, Laboratory of Tumor Immunology & Biology, Center for Cancer Research, National Cancer Center talks…
Phil Johnson, MS, RPh, Director of Pharmacy (Retired), Moffitt Cancer Center talks about Biosimilar Overview: Opportunities & Issues
Jeff Mortier talks about the latest information about the Cancer Payment Reform Bill.
At the Myeloma 2015 meeting, Prof Kenneth Anderson (Harvard Medical School, Boston, MA) chairs a discussion with Prof Jesús San…
At the Myeloma 2015 meeting, Dr Keith Stewart (Mayo Clinic, Scottsdale, AZ) chairs a discussion with Prof Gareth Morgan (University…
At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Matti Aapro (Clinique de Genolier, Genolier, Switzerland) discusses the…
Person they are interveiwng, their credentials
Bobbi Buell from onPoint Oncology talks about ICD-10 and what it means to oncology payments
Keith L. Knutson, PhD, Director, Cancer Vaccines and Immune Therapies Program, Vaccine & Gene Therapy Institute of Florida Practical Immuno-Oncology…
Laura Stevens, Program Director for CMMI Come Home Project talks about the Come Home Project and how it works.
Ricky Newton of COA talks about the new COPA program called Community Oncology Pharmacy Association at the COA annual meeting…
Ted Okon and Peter Yu, MD discuss new legislative issues associated with oncology for 2015 at the COA annual meeting…
Bo Gamble & Carol Murtaugh talk about What does it take to become a Oncology Medical Home at the annual…
On the first day of the Myeloma 2015 meeting, Dr Keith Stewart (Mayo Clinic, Scottsdale, AZ) chairs a discussion with…
Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York, NY) discusses the opportunities at the 14th St. Gallen International…
At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Véronique Diéras (Institut Curie, Paris, France) discusses the phase…
Kidney Cancer Organization Welcome Lyon Meeting 2015 Carolyn Konosky
Kidney Cancer Meeting Lyon, France 2015: Immunotherapy versus targeted treatments in metastatic renal cell carcinoma:The return game? Sylvie NEGRIER MD,…
Kidney Cancer Meeting Lyon, France 2015: Functional imaging in renal cancer: a 10 year history. Tom Powles Barts Cancer Institute…
Kidney Cancer Meeting Lyon, France 2015: Treatment beyond second line Camillo Porta Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation,…
Kidney Cancer Meeting Lyon, France 2015: Will Immunotherapy Marginalise Targeted Therapy to a Salvage Role by 2020? Tim Eisen University…
Kidney Cancer Meeting Lyon, France 2015: Have Results of Recent Randomized Trials Changed the Role of mTOR Inhibitors? Bernard Escudier…
Kidney Cancer Meeting Lyon, France 2015: What Have Sequencing Trials Taught Us?
Kidney Cancer Meeting Lyon, France 2015: Role of SBRT in the management of lung and liver metastases Ronan TANGUY, M.D.…
Kidney Cancer Meeting Lyon, France 2015: New target:FGFR & c-MET Laurence Albiges Gustave Roussy Institute, Dana-Farber Cancer Institute
Kidney Cancer Meeting Lyon, France 2015: 1st line treatment:what has changed in the last 2 years? Martin Gore PhD FRCP…
Kidney Cancer Meeting Lyon, France 2015: LOCAL TREATMENT FOR LUNG ET LIVER METASTASES SURGERY/ABLATION IS THE GOLD STANDARD – Alain…
Kidney Cancer Meeting Lyon, France 2015: Toxicity from Checkpoint Inhibitors James LarkinFRCP PhD
Kidney Cancer Meeting Lyon, France 2015: TKI drug interaction: what else do I need to know for my patient for…
Kidney Cancer Meeting Lyon, France 2015: Mechanisms and management of hypertension associated with anti-VEGF-treatment Stephane Ederhy Service de Cardiologie Hopital…
Kidney Cancer Meeting Lyon, France 2015: Skin Side Effects Associated with Kidney Cancer Treatment Christiane Thallinger, MD University of Vienna,…
Kidney Cancer Meeting Lyon, France 2015: Vaccines for RCC: Rationale and Clinical Update Hans Hammers M.D. / Ph.D. Assistant Professor:…
Kidney Cancer Meeting Lyon, France 2015: New Targets to Reverse VEGF Resistance Prof. Eric Raymond, MD, PhD Head of Medical…
Kidney Cancer Meeting Lyon, France 2015: T-Cell Checkpoints in RCC:Musings from a non-immunologist Primo N. Lara, Jr., M.D. Professor of…
Kidney Cancer Meeting Lyon, France 2015: Is renal cryoablation becoming an effective alternative to partial nephrectomy? J GARNON
Kidney Cancer Meeting Lyon, France 2015: Medical Oncologist and Urologist Different Views on Cytoreductive Nephrectomy? The Oncologists view Viktor Grünwald
Kidney Cancer Meeting Lyon, France 2015:Have Medical Oncologist and Urologist Different Views on Cytoreductive Nephrectomy? Axel Bex, The Netherlands Cancer…
Kidney Cancer Meeting Lyon, France 2015: Should we push for even more minimal invasive and conservative approaches in kidney cancer?…
Kidney Cancer Meeting Lyon, France 2015: Should we push even more for minimal invasive and conservative approaches in kidney cancer?…
Kidney Cancer Meeting Lyon, France 2015: Should We Now Biopsy Every Single Renal Tumor Before Treating? Bernard Escudier Institut Gustave…
Kidney Cancer Meeting Lyon, France 2015: SHOULD WE NOW BIOPSY EVERY SINGLE RENAL TUMOR BEFORE TREATING ? Alessandro VOLPE, M.D.…
Kidney Cancer Meeting Lyon, France 2015: John Fitzpatrick Tribute: Life in the Fast Lane
Kidney Cancer Meeting Lyon, France 2015: Immunotherapy for Kidney Cancer: Finally Center-Stage? Nizar M. Tannir, MD, FACP Professor and Deputy…
Kidney Cancer Meeting Lyon, France 2015: Clinical Relevance of Cancer Gene, James Brugarolas M.D., Ph.D. Kidney Cancer Program Leader Virginia…
Kidney Cancer Meeting Lyon, France 2015: Tribute to Pieter De Mulder by Hein Van Poppel Professor and Chairman UZ Leuven…
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Peter Schmid (Barts Cancer Institute, London, UK) discusses the…
Dr Matti Aapro (Clinique de Genolier, Genolier, Switzerland) discusses his highlights from the 14th St. Gallen International Breast Cancer Conference…
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Geoff Lindeman (The Walter and Eliza Hall Institute of…
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Paul Declerck (KU Leuven, Leuven, Belgium) discusses the understanding…
This is my interview with Jeri Francoeur, Breast Cancer Patient Advocate, breast cancer survivor, and President of the Susan G…
At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Richard Finn (UCLA, Los Angeles, CA) discusses the development…
At the 14th St. Gallen International Breast Cancer Conference (SG-BCC) 2015, Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New…
At the 14th St. Gallen International Breast Cancer Conference 2015, Dr John Bartlett (Ontario Institute for Cancer Research, Toronto, Canada)…
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Sibylle Loibl (German Breast Group, Neu-Isenburg, Germany) discusses recent…
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Giuseppe Viale (European Institute of Oncology and University of…
At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York,…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY)…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY)…
Immunotherapy Forum Video #28: Doctors are still weighing the pros and cons of giving a cancer patient immunotherapy before or…
At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York,…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) and Prof…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) and Prof…
What should be the protocol for a rising PSA in an undiagnosed patient? Dr. Geo Espinosa of NYU-Langone Medical Center…
Dr Giuseppe Curigliano (European Institute of Oncology, Milan, Italy) provides an overview of immune approaches for the treatment of breast…
At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Giuseppe Viale (European Institute of Oncology and University of…
Dr. Geo Espinosa of NYU-Langone Medical Center explains the concept of Integrative Urology – the union of traditional and complementary…
Dr. Lluis Cecchini of the Hospital del Mar in Barcelona talks about the necessity for patients to become more involved…
The European Board of Urology recently certified the Urology Department of the Hospital del Mar in Barcelona as a urological…
The European Board of Urology recently certified the Urology Department of the Hospital del Mar in Barcelona as a urological…
Immunotherapy Forum Video #26: Drs. Jared Weiss and Matthew Hellmann answer questions from the audience following their presentations on immunotherapy…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Andrew Davies (University of Southampton, Southampton, UK) discusses a…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Marek Trn?ný (Charles University Hospital, Prague, Czech Republic) discusses…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Martin Dreyling (Ludwig-Maximilians University of Munich, Munich, Germany) discusses…
http://cancerGRACE.org/ Immunotherapy Forum Video #24: In Part 1 of 2 videos, Dr. Matthew Hellmann provides an overview of clinical trials…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY)…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Umberto Vitolo (Città della Salute e della Scienza di…
Ted Okon Executive Director of COA conducts an interview with Author Siddhartha Mukherjee, MD and Producer/Director Barak Goodman about the…
At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Charles Swanton (London Research Institute and University College London,…
At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Charles Swanton (London Research Institute and University College London,…
At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Charles Swanton (London Research Institute and University College London,…
At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Jonathan Ledermann (University College London, UK) discusses the collaboration…
At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Charles Swanton (London Research Institute and University College London,…
At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Jonathan Ledermann (University College London, UK) discusses recent advances…
Reports emerging data about molecular subtyping of early-stage breast cancer and patients’ risk of disease recurrence Steven C. Shivers, PhD.,…
Genomic Profiling, African-American Women and Breast Cancer Risk
Gene Called USP9X and Tamoxifen Resistance
Metastatic Breast Cancer – ER-Positive – Dr. Eitan Amir summarizes the latest updates in ER positive breast cancer from the…
Biology and Pathology Insights – Dr. John Bartlett presented this session as a summary of the topic from original research…
Dr. John Bartlett Theranostic multiparametric tests improve residual risk assessment in early luminal breast cancer
Dr. Eileen Rakovitch A large prospectively-designed study of the DCIS score: Predicting recurrence risk after local excision for ductal carcinoma…
Surgical Oncology Highlights summarized from the San Antonio Breast Cancer Symposium sessions, and presented by Dr. Jean-Francois Boileau as part…
Radiation Oncology Highlights – Dr. Eileen Rakovitch summarizing top results from the San Antonio Breast Cancer Symposium
Advances in Early Breast Cancer (Chemotherapy and Targeted Therapy as well as Endocrine Therapy) are discussed by Dr. Maureen Trudeau…
Neoadjuvant Treatment of Breast Cancer – A summary of the San Antonio Breast Cancer Symposium 2014, during the OncologyEducation licensed…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Umberto Vitolo (Città della Salute e della Scienza di…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Simon Rule (Derriford Hospital, Plymouth, UK) discusses recent studies…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Anton Hagenbeek (Academic Medical Center, Amsterdam, Netherlands) discusses recent…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Simon Rule (Derriford Hospital, Plymouth, UK) discusses recent advances…
A summary of the new uses of immunotherapy and biomarkers in the treatment of NSCLC by Dr. Nayer Rizvi
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Christian Gisselbrecht (St. Louis Hospital, Paris, France) discusses recent…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Robin Foà (Sapienza University, Rome, Italy) discusses how understanding…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Rafael Fonseca (Mayo Clinic, Scottsdale, AZ) discusses multiple myeloma…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Bertrand Coiffier (Centre Hospitalier Lyon-Sud, Pierre-Benite, France) discusses a…
Prof Christian Gisselbrecht (St. Louis Hospital, Paris, France) discusses results of recent clinical studies in Hodgkin lymphoma (HL) presented at…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ola Landgren (Memorial Sloane Kettering Cancer Center, New York,…
Dr George Follows provides an overview of results of clinical trials in chronic lymphocytic leukaemia (CLL) presented at the 2014…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ian Flinn (Sarah Cannon Cancer Institute, Nashville, TN) discusses…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Bertrand Coiffier (Centre Hospitalier Lyon-Sud, Pierre-Benite, France) discusses the…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Christian Gisselbrecht (St. Louis Hospital, Paris, France) discusses the…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ian Flinn (Sarah Cannon Cancer Institute, Nashville, TN) discusses…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Bertrand Coiffier (Centre Hospitalier Lyon-Sud, Pierre-Benite, France) discusses the…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Anton Hagenbeek (Academic Medical Center, Amsterdam, Netherlands) discusses the…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ian Flinn (Sarah Cannon Cancer Institute, Nashville, TN) discusses…
Dr. Sunil Verma and Dr. Nadia Califaretti discuss case studies in breast cancer.
OncologyEducation.com presents: The CONCORD-2 study aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data,…
OncologyEducation.com presents: The CONCORD-2 study aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data,…
Armando and Jordan Lastra A Fathers Cancer and a Sons Careerbrought to you by The Community Oncology Alliance (COA) and…
Rob Rutigliano Testicular Cancer Would be Devastated if NSHOA closed brought to you by The Community Oncology Alliance (COA) and…
Jeffrey Vacirca, MD – CConquering Cancer Close to Home brought to you by The Community Oncology Alliance (COA) and The…
At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Susan Galbraith (Vice-President Oncology, AstraZeneca) discusses the National Lung…
At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Susan Galbraith (Vice-President Oncology, AstraZeneca) discusses the ongoing phase…
At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Rachel Humphrey (Senior Vice President, Head of Immuno-Oncology, AstraZeneca)…
At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Susan Galbraith (Vice-President Oncology, AstraZeneca) discusses the Study 19…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ola Landgren (Memorial Sloane Kettering Cancer Center, New York,…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Philippe Moreau (University Hospital of Nantes, France) discusses novel…
Thomas Mccloskey – Non Hodgkins Lymphoma Care Close to Home brought to you by The Community Oncology Alliance (COA) and…
Yelda Nouri, MD – Cancer Care, an MDs view brought to you by The Community Oncology Alliance (COA) and The…
Rick and Carrie Yanez Husband and Wife Diagnosed With Cancer brought to you by The Community Oncology Alliance (COA) and…
Dawn Savarese – What does a Chief Revenue Officer do at NSHOA? brought to you by The Community Oncology Alliance…
Ann and Bill An Ovarian Cancer Diagnosis In Sickness and in Health brought to you by The Community Oncology Alliance…
George Calcanes – What does the Chief Clinical Officer do at NSHOA brought to you by The Community Oncology Alliance…
Marie Ships and Merrianne Van Ness Diagnosed with Lung Cancer Received so much Support from NSHOA & her Sister brought…
Jeffrey Wong – What does a Pharmacy Techinician do at NSHOA? brought to you by The Community Oncology Alliance (COA)…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ola Landgren (Memorial Sloane Kettering Cancer Center, New York,…
Irene Trelfa Clinical Trial Participant: Breast Cancer I feel lucky to be a patient at NSHOA brought to you by…
Lynn Fitzpatrick – Nurse Educator North Shore Hematology Oncology brought to you by The Community Oncology Alliance (COA) and The…
Humberto Castro – Given Six Months to Live Now Tells Others Not to Give Up brought to you by The…
Diana Youngs – Everyone the Patient Meets in Community Oncology has Compassion for Patients brought to you by The Community…
Prof Paul Richardson (Dana-Farber Cancer Institute, Boston, MA) summarises of results of clinical trials in the management of relapsed or…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Maria-Victoria Mateos discusses an open-label, multicentre, phase Ib study…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffery Matous ((Colorado Blood Cancer Institute, Denver, CO) discusses…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffery Matous (Colorado Blood Cancer Institute, Denver, CO) discusses…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffery Matous (Colorado Blood Cancer Institute, Denver, CO) discusses…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Gareth Morgan (University of Arkansas for Medical Sciences, Little…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Maria-Victoria Mateos provides an update of a randomised, phase…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jean-Jacques Kiladjian (Hôpital Saint-Louis & Université Paris Diderot, Paris,…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Barbara Eichhorst (University Hospital, Cologne, Germany) discusses the BCL-2…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jean-Jacques Kiladjian (Hôpital Saint-Louis & Université Paris Diderot, Paris,…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Barbara Eichhorst (University Hospital, Cologne, Germany) discusses the final…
At the Thirteenth International Kidney Cancer Symposium, Dr Sumanta Pal (City of Hope Comprehensive Cancer Center, CA) discusses papillary renal…
At ESMO 2014, Prof Tom Powles (Barts Cancer Institute, UK) discusses strategies in the management of kidney cancer. Recent clinical…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr David Avigan (Harvard Medical School, Boston, MA) discusses recent…
Prof Claire Harrison (Guys and St Thomas NHS Foundation Trust, London, UK) discusses highlights on myeloproliferative neoplasms (MPNs) from the…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Denis-Claude Roy (University of Montreal, Montreal, Canada) discusses a…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Keith Stewart (Mayo Clinic, Scottsdale, AZ) discusses recent advances…
Stromal tumor-infiltrating lymphocytes(S-TILs): In the alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit
SABCS 2014: ECOG 1199 Trial Commentary by Dr. Sunil Verma: Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide…
SABCS 2014: TNT Trial Commentary by Dr. Sunil Verma: A randomized phase III trial of carboplatin (C) compared with docetaxel…
SABCS 2014: SOFT Trial Commentary by Dr. Sunil Verma: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS)…
The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with…
A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solventbased paclitaxel followed by anthracyline/ cyclophosphamide for…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Catherine Bollard (Children’s National Medical Center, Washington, DC), Dr…
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Stephan Grupp (Children’s Hospital of…
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Joseph Alvarnas (City of Hope…
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Craig Moskowitz (Memorial Sloan Kettering…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr David Steensma (Dana-Farber Cancer Institute, Boston, MA), Dr Brent…
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Farhad Ravandi (The University of…
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Eytan Stein (Memorial Sloan-Kettering Cancer…
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Oliver Ottmann (Goethe-University Hospital, Frankfurt,…
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Christoph Röllig (Universitätsklinikum Dresden, Dresden,…
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Wendy Stock (University of Chicago…
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Brent Wood (University of Washington,…
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Nicola Gökbuget (University Hospital Frankfurt,…
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Craig Moskowitz (Memorial Sloan Kettering…
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Brad Kahl (University of Wisconsin School of Medicine, Madison,…
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Philippe Armand (Dana-Farber Cancer Institute,…
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Thomas Martin (University of California…
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr MarÃa-Victoria Mateos (Hospital Universitario de…
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Keith Stewart (Mayo Clinic, Scottsdale,…
Dr Hans Hammers (Johns Hopkins, MD) discusses highlights from the Thirteenth International Kidney Cancer Symposium. Immunotherapies have received significant interest:…
At the Thirteenth International Kidney Cancer Symposium, Dr James Brugarolas (University of Texas Southwestern Medical Center, TX) discusses the clinical…
At the Thirteenth International Kidney Cancer Symposium, Dr James Hsieh (Memorial Sloan-Kettering Cancer Center, NY) discusses the progress in cancer…
At the Thirteenth International Kidney Cancer Symposium, Dr James Hsieh (Memorial Sloan-Kettering Cancer Center, NY) discusses the need for clinical…
At the Thirteenth International Kidney Cancer Symposium, Dr JianJun Gao (The University of Texas MD Anderson Cancer Center, TX) discusses…
At the Thirteenth International Kidney Cancer Symposium, Dr Abraham Ari Hakimi (Memorial Sloan-Kettering Cancer Center, NY) discusses recent developments in…
At the Thirteenth International Kidney Cancer Symposium, Dr Laurence Albiges (Gustave Roussy, France) provides an overview of papillary renal cell…
At the Thirteenth International Kidney Cancer Symposium, Dr Toni Choueiri (Dana-Farber Cancer Institute and Harvard Medical School, MA) discusses the…
At the Thirteenth International Kidney Cancer Symposium, Prof David Kwiatkowski (Brigham and Women’s Hospital, MA) discusses targeting the mTOR pathway…
At the Thirteenth International Kidney Cancer Symposium, Dr James Hsieh (Memorial Sloan-Kettering Cancer Center, NY) discusses chromophobe renal cell carcinoma…
At the Thirteenth International Kidney Cancer Symposium, Dr JianJun Gao (University of Texas MD Anderson Cancer Center, TX) provides an…
At the Thirteenth International Kidney Cancer Symposium, Dr Hans Hammers (Johns Hopkins, MD) encourages kidney cancer patients to take an…
At the Thirteenth International Kidney Cancer Symposium, Dr Hans Hammers (Johns Hopkins, MD) discusses the Phase 1 clinical trial that…
At the Thirteenth International Kidney Cancer Symposium, Dr Elizabeth Plimack (Fox Chase Cancer Center, PA) discusses highlights from the Thirteenth…
At the Thirteenth International Kidney Cancer Symposium, Dr Elizabeth Plimack (Fox Chase Cancer Center, PA) discusses prospective immunotherapy in kidney…
At the Thirteenth International Kidney Cancer Symposium, Dr Sumanta Pal (City of Hope Comprehensive Cancer Center, CA) discusses his research…
At the Thirteenth International Kidney Cancer Symposium, Dr Toni Choueiri (Dana-Farber Cancer Institute and Harvard Medical School, MA) provides an…
At the Thirteenth International Kidney Cancer Symposium, Dr Abraham Ari Hakimi (Memorial Sloan-Kettering Cancer Center, NY) discusses the current understanding…
At the Thirteenth International Kidney Cancer Symposium, Carolyn Konosky (Kidney Cancer Association, IL) encourages kidney cancer patients to have an…
At the Thirteenth International Kidney Cancer Symposium, Carolyn Konosky (Kidney Cancer Association, IL) provides an overview of the Kidney Cancer…
Latest Lung Cancer Updates from ESMO 2014 – Chemotherapy Advances by Dr. Sunil Verma
Latest Lung Cancer Updates from ESMO 2014 – Advances in ALK Positive NSCLC by Dr. Sunil Verma
Dr. James Brugarolas, M.D., Ph.D. Kidney Cancer Program Leader Associate Professor of Internal Medicine & Developmental Biology University of Texas…
Bernard J. Escudier, M.D. accepts the 2014 Eugene P. Schonfeld Award at the Kidney Cancer meeting in Chicago
Dr. Hiral D. Parekh, M.D. discusses Cost Analysis of an Initial Observation Approach in Metastatic Renal Cell Carcinoma at the…
Dr. Laurence Albiges, M.D., Ph.D. discusses Differential expression of c-MET between primary and metastatic sites in clear cell Renal Cell…
Dr. Andre P. Fay, M.D. discusses Whole-Exome Sequencing Predicting Two Extreme Phenotypes of Response to VEGF-targeted Therapies in Patients with…
Dr. Joshua Lang, M.D., M.S. discusses Development of Pharmacodynamic Biomarkers in Circulating Renal Cancer Cells at the Kidney Cancer meeting…
Dr. Andrew G. Winer discusses Tumor Purity and Immune Cell Infiltration as a Prognostic Risk Predictor for Clear Cell Renal…
Dr. David Kwiatkowski talks about The mTOR signaling pathwayWho responds to rapalogs and why? at the Kidney Cancer meeting in…
Dr. Harriet Kluger, M.D.Associate Professor Yale Cancer Center discusses The Met Pathway as a Target in RCC at the Kidney…
Dr. David F. McDermott discusses Immune correlates and long-term follow-up of a Phase Ia study of MPDL3280A, an engineered PD-L1…
Dr. Thai Ho, M.D., Ph.D.Mayo Clinic Arizona discusses The Evolving Role of Chromatin and Epigenetics in RCC at the Kidney…
Dr. Toni K. Choueiri discusses Risk Factors and a Model to Predict Toxicity-related Treatment Discontinuation in Patients with Metastatic Renal…
Dr. Sumanta K. Pal, MD;1 Min Li, PhD;2 Xiwei Wu, PhD;3 Paul Frankel, PhD2 Â 1Department of Medical Oncology, City…
Dr. Georg A. BjarnasonDivision of Medical OncologySunnybrook Odette Cancer CentreAssociate Professor, Faculty of Medicine, University of Toronto discusses Dose Reduction or…
Dr. David I. Quinn MBBS (Hons) PhD FRACP FACP Associate Professor of Medicine Chief, Section of GU Medical Oncology Division…
Dr. Frede Donskov, M.D., PhD Chair, Danish Renal Cancer Group, DARENCA Aarhus University Hospital Denmark discusses Toxicity as a Biomarker…
Suzanne L. Topalian of Johns Hopkins University School of Medicine Sidney Kimmel Comprehensive Cancer Center discusses Biomarkers for PD-1 checkpoint…
Dr. Drew Pardoll of Johns Hopkins discusses Basic Concepts and Future Horizons in Cancer Immunotherapy at the Kidney Cancer Meeting…
Elizabeth R. Plimack MD MS Director, Genitourinary Clinical Research Associate Professor, Department of Hematology/Oncology discusses Combination immunotherapy + VEGF targeted…
M. Dror Michaelson, MD PhD MGH Cancer CenterBoston, MA discusses how TKIs are the Optimal Front-Line mRCC Treatment